A Phase 1 interventional study of bortezomib and bortezomib, rifampicin in Multiple Myeloma and Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-30.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 83rd largest by enrollment of the 267 interventional ones that give a count, is one of 15 that started in 2007, is one of 41 in phase 1, and was the 85th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 15 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
54 studies in Multiple Myeloma by Takeda: 2 open now, 4 under way, 1 of them phase 3. Of 47 finished, 33 (70%) have results posted.
Among the 54 studies in Multiple Myeloma by Takeda, this one is the 17th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2007, is one of 12 in phase 1, and was the 10th registered.
Takeda’s Multiple Myeloma studies by the year they started, since 2002.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Takeda’s 54 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib). Rifampicin will be used to assess the effect of a strong CYP3A4 inducer and dexamethasone to assess the effect of a relatively weak inducer. This study is also to evaluate the impact of CYP3A4 inducers on the pharmacodynamics (PD) of VELCADE and the safety profile of VELCADE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of disallowed therapies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
Drug: bortezomib
Treatment Arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
Drug: bortezomib, rifampicin
Treatment arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
Drug: bortezomib, dexamethasone
1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
Also known as: VELCADE
Drug pages: Bortezomib · Rifampin
bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
Also known as: bortezomib, rifampicin
Drug pages: Bortezomib · Dexamethasone
bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
Also known as: bortezomib, dexamethasone
Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours
Time frame: Cycle 3 day 14 (72 hours post last dose)
| Milestone | VELCADE | VELCADE + Rifampicin | VELCADE + Dexamethasone |
|---|---|---|---|
| Started | 30 | 13 | 18 |
| Completed | 18 | 13 | 17 |
| Not completed | 12 | 0 | 1 |
| Withdrew: Adverse event | 6 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 |
| ng*h/mL | VELCADE + Rifampicin | VELCADE + Dexamethasone | VELCADE |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours | 123 ± 34.2 | 170 ± 64.5 | 215 ± 58.4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VELCADE | — | 14/30 (46.7%) | 28/30 (93.3%) |
| VELCADE + Rifampicin | — | 5/13 (38.5%) | 13/13 (100%) |
| VELCADE + Dexamethasone | — | 7/18 (38.9%) | 18/18 (100%) |
| Event | VELCADE | VELCADE + Rifampicin | VELCADE + Dexamethasone |
|---|---|---|---|
| Renal FailureRenal and urinary disorders | 0/30 | 0/13 | 3/18 |
| DiarrhoeaGastrointestinal disorders | 1/30 | 1/13 | 2/18 |
| Upper Gastrointestinal HaemorrhageGastrointestinal disorders | 0/30 | 1/13 | 0/18 |
| FatigueGeneral disorders | 0/30 | 1/13 | 0/18 |
| PyrexiaGeneral disorders | 1/30 | 1/13 | 0/18 |
| CellulitisInfections and infestations | 0/30 | 1/13 | 0/18 |
| Device Related InfectionInfections and infestations | 0/30 | 1/13 | 1/18 |
| DehydrationMetabolism and nutrition disorders | 0/30 | 1/13 | 1/18 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/30 | 1/13 | 0/18 |
| Circulatory CollapseVascular disorders | 0/30 | 1/13 | 0/18 |
| Event | VELCADE | VELCADE + Rifampicin | VELCADE + Dexamethasone |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 7/30 | 6/13 | 10/18 |
| Peripheral Sensory NeuropathyNervous system disorders | 7/30 | 6/13 | 10/18 |
| NauseaGastrointestinal disorders | 11/30 | 7/13 | 6/18 |
| VomitingGastrointestinal disorders | 8/30 | 6/13 | 3/18 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/30 | 5/13 | 8/18 |
| Upper Respiratory Tract InfectionInfections and infestations | 7/30 | 2/13 | 7/18 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 6/30 | 5/13 | 4/18 |
| DizzinessNervous system disorders | 5/30 | 5/13 | 2/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/30 | 5/13 | 1/18 |
| HeadacheNervous system disorders | 11/30 | 3/13 | 4/18 |
| Age, Categorical(Participants) | VELCADE | VELCADE + Rifampicin | VELCADE + Dexamethasone | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 8 | 8 | 30 |
| >=65 years | 16 | 5 | 10 | 31 |
| Age Continuous(years) | VELCADE | VELCADE + Rifampicin | VELCADE + Dexamethasone | Total |
|---|---|---|---|---|
| Mean | 64.7 ± 10.86 | 60.2 ± 9.97 | 62.3 ± 11.72 | 63.0 ± 10.91 |
| Sex: Female, Male(Participants) | VELCADE | VELCADE + Rifampicin | VELCADE + Dexamethasone | Total |
|---|---|---|---|---|
| Female | 15 | 7 | 9 | 31 |
| Male | 15 | 6 | 9 | 30 |
The record gives a start of Sep 2007, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bortezomib · Rifampin · Dexamethasone
Millennium Pharmaceuticals, Inc. →